Overview

Study of Intermittent OSI-906 Dosing

Status:
Completed

Trial end date:
2010-09-20

Target enrollment:

Participant gender:

Summary

Multicenter, open-label, phase 1, cohort dose escalation study to determine the maximum tolerated dose (MTD) of 3 intermittent OSI-906 dosing schedules.

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma Inc